Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.25.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 287,688 $ 88,033
Accounts receivable, net 194,442 0
Grant receivable 761,515 0
Inventory 155,367 0
Prepaid expenses 63,164 29,963
Total current assets 1,462,176 117,996
Property and equipment, net 7,685 18,977
Right to use assets 169,443 199,184
Other assets:    
Intangible assets, net 3,011,833 7,848
Goodwill 2,840,400 0
Deposits, long term 41,936 41,936
Total other assets 5,894,169 49,784
Total assets 7,533,473 385,941
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $1,629,743 and $1,349,465, respectively 12,400,939 5,574,831
Deferred revenue-grant 56,590 56,590
Lease liability, short term 41,686 40,057
Notes payable, net of debt discount of $3,216 and $41,452 1,547,853 1,343,278
Notes payable, related parties 991,059 1,192,859
Total current liabilities 15,038,127 8,207,615
Long term liabilities:    
EIDL loan, long term 69,803 71,029
Upfront purchase price liability 85,440 0
Royalty liability 317,577 0
Royalty obligation, net of discount of $4,184,810 and $4,418,698, related parties 4,659,064 4,303,402
Lease liability, long term 127,757 159,127
Total liabilities 20,297,768 12,741,173
Deficit:    
Preferred stock, no par value; 600,000 shares authorized at September 30, 2025 and December 31, 2024 0 0
Common stock, $0.001 par value; 750,000,000 shares authorized, 20,188,029 and 13,299,349 shares issued and outstanding as of as of September 30, 2025 and December 31, 2024, respectively 20,188 13,299
Common stock subscribed 100,000 100,000
Additional paid in capital 73,575,400 70,953,807
Accumulated deficit (87,201,843) (83,209,142)
Total deficit attributable to BioCorRx, Inc. (13,484,639) (12,120,420)
Non-controlling interest 720,344 (234,812)
Total deficit (12,764,295) (12,355,232)
Total liabilities and deficit 7,533,473 385,941
Series A Convertible Preferred Stock [Member]    
Deficit:    
Preferred stock, no par value; 600,000 shares authorized at September 30, 2025 and December 31, 2024 16,000 16,000
Series B Convertible Preferred Stock [Member]    
Deficit:    
Preferred stock, no par value; 600,000 shares authorized at September 30, 2025 and December 31, 2024 $ 5,616 $ 5,616